/
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, and a pipeline of clinical and preclinical candidates in development for neurological disorders.
17.21% operating margin is respectable but not wide. ROIC at 11.91%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue declined 5.2% YoY. Margins deteriorated 9.8pp alongside, both lines moving the wrong way.
ROIC dropped from 22.41% to 11.91%, capital efficiency is deteriorating. Operating margin contracted 9.8pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$1.56B
▼ -5.2% YoY
Net Income (TTM)
$153M
▼ -34.2% YoY
Op. Margin
12.28%
▼ -9.8pp YoY
ROIC
6.44%
▼ -10.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$222M
▲ +18.4% YoY
Op. Cash Flow (TTM)
$256M
▲ +18.6% YoY
Net Debt
$1.07B
Cash & Equiv.
$512M
5Y CAGR: +7.3%
5Y CAGR: +63.9%
Continue Research